Physician profile
Larry Sanders
NPI 1790813608
$759,563.66
in general payments reported to CMS, 2019-2025
24 companies · $133K in 2025
The $133K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117K · 2020: $64K · 2021: $84K · 2022: $91K · 2023: $138K · 2024: $133K · 2025: $133K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $356K · Travel and Lodging: $29K · Food and Beverage: $9,850 · Honoraria: $9,350 · Education: $69.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $356,075.00 |
| Travel and Lodging | $29,088.22 |
| Food and Beverage | $9,849.99 |
| Honoraria | $9,350.00 |
| Education | $69.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $546,653.10 | 2021-2025 | Vraylar |
| Allergan, INC. | $165,273.77 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17,032.60 | 2019-2025 | Trintellix |
| Axsome Therapeutics, INC. | $10,798.69 | 2023-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $9,121.74 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $5,569.55 | 2022 | |
| Eisai INC. | $1,673.73 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $754.95 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $671.71 | 2019-2025 | Ingrezza |
| Alkermes, INC. | $625.16 | 2019-2025 | Aristada, Lybalvi |
| Ironshore Pharmaceuticals INC. | $210.75 | 2019-2020 | |
| Lundbeck LLC | $206.57 | 2019-2023 | Rexulti |
| Corium, LLC | $195.10 | 2022-2024 | Azstarys |
| Idorsia Pharmaceuticals US INC | $133.87 | 2023 | Quviviq |
| Vanda Pharmaceuticals INC. | $124.45 | 2024 | Fanapt |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $108.52 | 2019 | |
| Arbor Pharmaceuticals, INC. | $89.79 | 2019-2020 | |
| Adlon Therapeutics L.P. | $85.75 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $72.77 | 2019-2023 | Austedo Xr, Austedo |
| Bausch Health US, LLC | $54.64 | 2019-2020 | |
| Shire North American Group INC | $48.45 | 2019 | |
| Tris Pharma INC | $45.53 | 2019 | |
| Vertical Pharmaceuticals, LLC | $12.47 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Sanders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.